Pathogenesis of Bronchopulmonary Dysplasia

Seminars in Perinatology

Volumn 30, Issue 4, 2006, Pages 171-178

  Chess, Patricia R ^a   D'Angio, Carl T ^a   Pryhuber, Gloria S ^a   Maniscalco, William M ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

arrested pulmonary development; bronchopulmonary dysplasia; inflammation; patent ductus arteriosus; respiratory distress syndrome; surfactant deficiency

Indexed keywords

ENDOTHELIAL MONOCYTE ACTIVATING POLYPEPTIDE II; ENDOTOXIN; INDOMETACIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; OXYGEN; SURFACTANT; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANTIBIOTIC THERAPY; ARTIFICIAL VENTILATION; CALORIC RESTRICTION; CHORIOAMNIONITIS; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; GENETIC PREDISPOSITION; GENETICS; GESTATIONAL AGE; HUMAN; HYPEROXIA; HYPOXIA; INFLAMMATION; LOW BIRTH WEIGHT; LUNG BLOOD FLOW; LUNG COMPLIANCE; LUNG DEVELOPMENT; LUNG DYSPLASIA; LUNG EDEMA; LUNG FIBROSIS; LUNG LAVAGE; LUNG SHUNTING; MORPHOGENESIS; NONHUMAN; NUTRITION; NUTRITIONAL SUPPORT; OXYGEN SATURATION; PATENT DUCTUS ARTERIOSUS; PATHOPHYSIOLOGY; POSITIVE END EXPIRATORY PRESSURE; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; REVIEW; RISK FACTOR; RODENT; SEPSIS; TIDAL VOLUME;

BRONCHOPULMONARY DYSPLASIA; FLUID THERAPY; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFLAMMATION; LUNG; OXYGEN; PULMONARY SURFACTANTS; RESPIRATION, ARTIFICIAL; RISK FACTORS;

EID: 33745965118     PISSN: 01460005     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semperi.2006.05.003     Document Type: Review

References (109)

1. Martin J.A., Hamilton B.E., Sutton P.D., et al. Births. final data for 2003. Natl Vital Stat Rep 54 (2005) 1-116
2. Ehrenkranz R.A., Walsh M.C., Vohr B.R., et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 116 (2005) 1353-1360
3. Northway Jr. W.H., Rosan R.C., and Porter D.Y. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 276 (1967) 357-368
4. Pierce M.R., and Bancalari E. The role of inflammation in the pathogenesis of bronchopulmonary dysplasia. Pediatr Pulmonol 19 (1995) 371-378
5. Jobe A.J. The new BPD. an arrest of lung development. Pediatr Res 46 (1999) 641-643
6. Bancalari E. Changes in the pathogenesis and prevention of chronic lung disease of prematurity. Am J Perinatol 18 (2001) 1-9
7. Rojas M.A., Gonzalez A., Bancalari E., et al. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr 126 (1995) 605-610
8. Charafeddine L., D'Angio C.T., and Phelps D.L. Atypical chronic lung disease patterns in neonates. Pediatrics 103 (1999) 759-765
9. D'Angio C.T., Finkelstein J.N., Lomonaco M.B., et al. Changes in surfactant protein gene expression in a neonatal rabbit model of hyperoxia-induced fibrosis. Am J Physiol 272 (1997) L720-L730
10. Bonikos D.S., Bensch K.G., and Northway Jr. W.H. Oxygen toxicity in the newborn. The effect of chronic continuous 100 percent oxygen exposure on the lungs of newborn mice. Am J Pathol 85 (1976) 623-650
11. Coalson J.J. Experimental models of bronchopulmonary dysplasia. Biol Neonate 71 suppl 1 (1997) 35-38
12. Bland R.D. Neonatal chronic lung disease in the post-surfactant era. Biol Neonate 88 (2005) 181-191
13. Davis J.M., Dickerson B., Metlay L., and Penney D.P. Differential effects of oxygen and barotrauma on lung injury in the neonatal piglet. Pediatr Pulmonol 10 (1991) 157-163
14. Delemos R.A., Coalson J.J., Gerstmann D.R., et al. Oxygen toxicity in the premature baboon with hyaline membrane disease. Am Rev Respir Dis 136 (1987) 677-682
15. Coalson J.J., Winter V.T., Siler-Khodr T., and Yoder B.A. Neonatal chronic lung disease in extremely immature baboons. Am J Respir Crit Care Med 160 (1999) 1333-1346
16. Saugstad O.D., Ramji S., and Vento M. Resuscitation of depressed newborn infants with ambient air or pure oxygen. a meta-analysis. Biol Neonate 87 (2005) 27-34
17. Vento M., Asensi M., Sastre J., et al. Oxidative stress in asphyxiated term infants resuscitated with 100% oxygen. J Pediatr 142 (2003) 240-246
18. Vento M., Asensi M., Sastre J., et al. Resuscitation with room air instead of 100% oxygen prevents oxidative stress in moderately asphyxiated term neonates. Pediatrics 107 (2001) 642-647
19. Ogihara T., Kim H.S., Hirano K., et al. Oxidation products of uric acid and ascorbic acid in preterm infants with chronic lung disease. Biol Neonate 73 (1998) 24-33
20. Winterbourn C.C., Chan T., Buss I.H., et al. Protein carbonyls and lipid peroxidation products as oxidation markers in preterm infant plasma. associations with chronic lung disease and retinopathy and effects of selenium supplementation. Pediatr Res 48 (2000) 84-90
21. Van Marter L.J., Allred E.N., Pagano M., et al. Do clinical markers of barotrauma and oxygen toxicity explain interhospital variation in rates of chronic lung disease? The Neonatology Committee for the Developmental Network. Pediatrics 105 (2000) 1194-1201
22. Tin W., Milligan D.W., Pennefather P., and Hey E. Pulse oximetry, severe retinopathy, and outcome at one year in babies of less than 28 weeks gestation. Arch Dis Child Fetal Neonatal Ed 84 (2001) F106-F110
23. Group TS-RMS. Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I. Primary outcomes. Pediatrics 105 (2000) 295-310
24. Askie L.M., Henderson-Smart D.J., Irwig L., and Simpson J.M. Oxygen-saturation targets and outcomes in extremely preterm infants. N Engl J Med 349 (2003) 959-967
25. Burri P.H., and Weibel E.R. Morphometric estimation of pulmonary diffusion capacity. II. Effect of Po2 on the growing lung, adaption of the growing rat lung to hypoxia and hyperoxia. Respir Physiol 11 (1971) 247-264
26. Farrell P.A., and Fiascone J.M. Bronchopulmonary dysplasia in the 1990s. a review for the pediatrician. Curr Probl Pediatr 27 (1997) 129-163
27. Reynolds E.O., Roberton N.R., and Wigglesworth J.S. Hyaline membrane disease, respiratory distress, and surfactant deficiency. Pediatrics 42 (1968) 758-768
28. Kendig J.W., Notter R.H., Cox C., et al. A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks' gestation. N Engl J Med 324 (1991) 865-871
29. Bancalari E., and del Moral T. Bronchopulmonary dysplasia and surfactant. Biol Neonate 80 suppl 1 (2001) 7-13
30. Merrill J.D., Ballard R.A., Cnaan A., et al. Dysfunction of pulmonary surfactant in chronically ventilated premature infants. Pediatr Res 56 (2004) 918-926
31. Ballard P.L., Gonzales L.W., Godinez R.I., et al. Surfactant composition and function in a primate model of infant chronic lung disease. effects of inhaled nitric oxide. Pediatr Res 59 (2006) 157-162
32. Attar M.A., and Donn S.M. Mechanisms of ventilator-induced lung injury in premature infants. Semin Neonatol 7 (2002) 353-360
33. Thome U.H., Carlo W.A., and Pohlandt F. Ventilation strategies and outcome in randomised trials of high frequency ventilation. Arch Dis Child Fetal Neonatal Ed 90 (2005) F466-F473
34. Strand M., Ikegami M., and Jobe A.H. Effects of high PCO2 on ventilated preterm lamb lungs. Pediatr Res 53 (2003) 468-472
35. D'Angio C.T., Chess P.R., Kovacs S.J., et al. Pressure-regulated volume control ventilation vs synchronized intermittent mandatory ventilation for very low-birth-weight infants. a randomized controlled trial. Arch Pediatr Adolesc Med 159 (2005) 868-875
36. Charles P.E., Martin L., Etienne M., et al. Influence of positive end-expiratory pressure (PEEP) on histopathological and bacteriological aspects of pneumonia during low tidal volume mechanical ventilation. Intensive Care Med 30 (2004) 2263-2270
37. Chu E.K., Whitehead T., and Slutsky A.S. Effects of cyclic opening and closing at low- and high-volume ventilation on bronchoalveolar lavage cytokines. Crit Care Med 32 (2004) 168-174
38. Meredith K.S., deLemos R.A., Coalson J.J., et al. Role of lung injury in the pathogenesis of hyaline membrane disease in premature baboons. J Appl Physiol 66 (1989) 2150-2158
39. Gerstmann D.R., deLemos R.A., Coalson J.J., et al. Influence of ventilatory technique on pulmonary baroinjury in baboons with hyaline membrane disease. Pediatr Pulmonol 5 (1988) 82-91
40. Mariani G., Cifuentes J., and Carlo W.A. Randomized trial of permissive hypercapnia in preterm infants. Pediatrics 104 (1999) 1082-1088
41. Gaynor E.B., and Danoff S.J. The role of gentle ventilation in prevention of subglottic stenosis in the newborn. Otolaryngol Head Neck Surg 109 (1993) 701-706
42. Donn S.M., and Sinha S.K. Can mechanical ventilation strategies reduce chronic lung disease?. Semin Neonatol 8 (2003) 441-448
43. Woodgate P.G., and Davies M.W. Permissive hypercapnia for the prevention of morbidity and mortality in mechanically ventilated newborn infants. Cochrane Database Syst Rev 2 (2001) CD002061
44. Moschopulos M., and Burri P.H. Morphometric analysis of fetal rat lung development. Anat Rec 237 (1993) 38-48
45. Burri P.H. Fetal and postnatal development of the lung. Annu Rev Physiol 46 (1984) 617-628
46. van Tuyl M., Liu J., Wang J., et al. Role of oxygen and vascular development in epithelial branching morphogenesis of the developing mouse lung. Am J Physiol Lung Cell Mol Physiol 288 (2005) L167-L178
47. Schwarz M.A., Zhang F., Lane J.E., et al. Angiogenesis and morphogenesis of murine fetal distal lung in an allograft model. Am J Physiol Lung Cell Mol Physiol 278 (2000) L1000-L1007
48. Jakkula M., Le Cras T.D., Gebb S., et al. Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol 279 (2000) L600-L607
49. Gerber H.P., McMurtrey A., Kowalski J., et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273 (1998) 30336-30343
50. Alon T., Hemo I., Itin A., et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1 (1995) 1024-1028
51. Bhatt A.J., Amin S.B., Chess P.R., et al. Expression of vascular endothelial growth factor and Flk-1 in developing and glucocorticoid-treated mouse lung. Pediatr Res 47 (2000) 606-613
52. Galambos C., Ng Y.S., Ali A., et al. Defective pulmonary development in the absence of heparin-binding vascular endothelial growth factor isoforms. Am J Respir Cell Mol Biol 27 (2002) 194-203
53. Akeson A.L., Greenberg J.M., Cameron J.E., et al. Temporal and spatial regulation of VEGF-A controls vascular patterning in the embryonic lung. Dev Biol 264 (2003) 443-455
54. McGrath-Morrow S.A., Cho C., Cho C., et al. Vascular endothelial growth factor receptor 2 blockade disrupts postnatal lung development. Am J Respir Cell Mol Biol 32 (2005) 420-427
55. Brown K.R., England K.M., Goss K.L., et al. VEGF induces airway epithelial cell proliferation in human fetal lung in vitro. Am J Physiol Lung Cell Mol Physiol 281 (2001) L1001-L1010
56. Raoul W., Chailley-Heu B., Barlier-Mur A.M., et al. Effects of vascular endothelial growth factor on isolated fetal alveolar type II cells. Am J Physiol Lung Cell Mol Physiol 286 (2004) L1293-L1301
57. Maniscalco W.M., Watkins R.H., Pryhuber G.S., et al. Angiogenic factors and alveolar vasculature. development and alterations by injury in very premature baboons. Am J Physiol Lung Cell Mol Physiol 282 (2002) L811-L823
58. Bland R.D., Albertine K.H., Carlton D.P., et al. Chronic lung injury in preterm lambs. abnormalities of the pulmonary circulation and lung fluid balance. Pediatr Res 48 (2000) 64-74
59. Quintos-Alagheband M.L., White C.W., and Schwarz M.A. Potential role for antiangiogenic proteins in the evolution of bronchopulmonary dysplasia. Antioxid Redox Signal 6 (2004) 137-145
60. Roberts R.J., Weesner K.M., and Bucher J.R. Oxygen-induced alterations in lung vascular development in the newborn rat. Pediatr Res 17 (1983) 368-375
61. Warner B.B., Stuart L.A., Papes R.A., and Wispe J.R. Functional and pathological effects of prolonged hyperoxia in neonatal mice. Am J Physiol 275 (1998) L110-L117
62. Maniscalco W.M., Watkins R.H., Dangio C.T., and Ryan R.M. Hyperoxic injury decreases alveolar epithelial cell expression of vascular endothelial growth factor (VEGF) in neonatal rabbit lung. Am J Respir Cell Mol Biol 16 (1997) 557-567
63. Hosford G.E., and Olson D.M. Effects of hyperoxia on VEGF, its receptors, and HIF-2alpha in the newborn rat lung. Am J Physiol Lung Cell Mol Physiol 285 (2003) L161-L168
64. Kunig A.M., Balasubramaniam V., Markham N.E., et al. Recombinant human VEGF treatment enhances alveolarization after hyperoxic lung injury in neonatal rats. Am J Physiol Lung Cell Mol Physiol 289 (2005) L529-L535
65. Thebaud B., Ladha F., Michelakis E.D., et al. Vascular endothelial growth factor gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxia-induced lung injury. evidence that angiogenesis participates in alveolarization. Circulation 112 (2005) 2477-2486
66. Coalson J. Pathology of chronic lung disease in early infancy. In: Bland R., and Coalson J. (Eds). Chronic Lung Disease in Early Infancy vol. 137 (2000), Marcel Dekker, New York, NY 85-124
67. Bhatt A.J., Pryhuber G.S., Huyck H., et al. Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. Am J Respir Crit Care Med 164 (2001) 1971-1980
68. Thibeault D.W., Mabry S.M., Norberg M., et al. Lung microvascular adaptation in infants with chronic lung disease. Biol Neonate 85 (2004) 273-282
69. Lassus P., Turanlahti M., Heikkila P., et al. Pulmonary vascular endothelial growth factor and Flt-1 in fetuses, in acute and chronic lung disease, and in persistent pulmonary hypertension of the newborn. Am J Respir Crit Care Med 164 (2001) 1981-1987
70. De Paepe M.E., Mao Q., Powell J., et al. Growth of pulmonary microvasculature in ventilated preterm infants. Am J Respir Crit Care Med 173 (2006) 204-211
71. Asikainen T.M., Ahmad A., Schneider B.K., et al. Effect of preterm birth on hypoxia-inducible factors and vascular endothelial growth factor in primate lungs. Pediatr Pulmonol 40 (2005) 538-546
72. Jobe A.H., and Ikegami M. Mechanisms initiating lung injury in the preterm. Early Hum Dev 53 (1998) 81-94
73. Le Cras T.D., Hardie W.D., Deutsch G.H., et al. Transient induction of TGF-alpha disrupts lung morphogenesis, causing pulmonary disease in adulthood. Am J Physiol Lung Cell Mol Physiol 287 (2004) L718-L729
74. Kallapur S.G., Bachurski C.J., Le Cras T.D., et al. Vascular changes after intra-amniotic endotoxin in preterm lamb lungs. Am J Physiol Lung Cell Mol Physiol 287 (2004) L1178-L1185
75. Viscardi R.M., Muhumuza C.K., Rodriguez A., et al. Inflammatory markers in intrauterine and fetal blood and cerebrospinal fluid compartments are associated with adverse pulmonary and neurologic outcomes in preterm infants. Pediatr Res 55 (2004) 1009-1017
76. Watterberg K.L., Demers L.M., Scott S.M., et al. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics 97 (1996) 210-215
77. Van Marter L.J., Dammann O., Allred E.N., et al. Chorioamnionitis, mechanical ventilation, and postnatal sepsis as modulators of chronic lung disease in preterm infants. J Pediatr 140 (2002) 171-176
78. Speer C.P. Inflammation and bronchopulmonary dysplasia. Semin Neonatol 8 (2003) 29-38
79. Baier R.J., Loggins J., and Kruger T.E. Monocyte chemoattractant protein-1 and interleukin-8 are increased in bronchopulmonary dysplasia. relation to isolation of Ureaplasma urealyticum. J Invest Med 49 (2001) 362-369
80. Kakkera D.K., Siddiq M.M., and Parton L.A. Interleukin-1 balance in the lungs of preterm infants who develop bronchopulmonary dysplasia. Biol Neonate 87 (2005) 82-90
81. Kazzi S.N., Romero R., McLaughlin K., et al. Serial changes in levels of IL-6 and IL-1beta in premature infants at risk for bronchopulmonary dysplasia. Pediatr Pulmonol 31 (2001) 220-226
82. Witt A., Berger A., Gruber C.J., et al. Increased intrauterine frequency of Ureaplasma urealyticum in women with preterm labor and preterm premature rupture of the membranes and subsequent cesarean delivery. Am J Obstet Gynecol 193 (2005) 1663-1669
83. Gomez R., Ghezzi F., Romero R., et al. Premature labor and intra-amniotic infection. Clinical aspects and role of the cytokines in diagnosis and pathophysiology. Clin Perinatol 22 (1995) 281-342
84. Witt A., Berger A., Gruber C.J., et al. IL-8 concentrations in maternal serum, amniotic fluid and cord blood in relation to different pathogens within the amniotic cavity. J Perinat Med 33 (2005) 22-26
85. van Waarde W.M., Brus F., Okken A., et al. Ureaplasma urealyticum colonization, prematurity and bronchopulmonary dysplasia. Eur Respir J 10 (1997) 886-890
86. Massaro D., and Massaro G.D. Critical period for alveologenesis and early determinants of adult pulmonary disease. Am J Physiol Lung Cell Mol Physiol 287 (2004) L715-L717
87. Northway Jr. W.H. Bronchopulmonary dysplasia. thirty-three years later. Pediatr Pulmonol Suppl 23 (2001) 5-7
88. Oh W., Poindexter B.B., Perritt R., et al. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants. J Pediatr 147 (2005) 786-790
89. Tammela O.K., and Koivisto M.E. Fluid restriction for preventing bronchopulmonary dysplasia? Reduced fluid intake during the first weeks of life improves the outcome of low-birth-weight infants. Acta Paediatr 81 (1992) 207-212
90. Perez Fontan J.J., Clyman R.I., Mauray F., et al. Respiratory effects of a patent ductus arteriosus in premature newborn lambs. J Appl Physiol 63 (1987) 2315-2324
91. Alpan G., Mauray F., and Clyman R.I. Effect of patent ductus arteriosus on water accumulation and protein permeability in the lungs of mechanically ventilated premature lambs. Pediatr Res 26 (1989) 570-575
92. Alpan G., Scheerer R., Bland R., et al. Patent ductus arteriosus increases lung fluid filtration in preterm lambs. Pediatr Res 30 (1991) 616-621
93. Bell E.F., Warburton D., Stonestreet B.S., and Oh W. Effect of fluid administration on the development of symptomatic patent ductus arteriosus and congestive heart failure in premature infants. N Engl J Med 302 (1980) 598-604
94. Van Marter L.J., Leviton A., Allred E.N., et al. Hydration during the first days of life and the risk of bronchopulmonary dysplasia in low birth weight infants. J Pediatr 116 (1990) 942-949
95. Van Marter L.J., Pagano M., Allred E.N., et al. Rate of bronchopulmonary dysplasia as a function of neonatal intensive care practices. J Pediatr 120 (1992) 938-946
96. Donahue M.L., Phelps D.L., Richter S.E., et al. A semipermeable skin dressing for extremely low birth weight infants. J Perinatol 16 (1996) 20-26
97. Bhandari V., Brodsky N., and Porat R. Improved outcome of extremely low birth weight infants with Tegaderm application to skin. J Perinatol 25 (2005) 276-281
98. Bancalari E., Claure N., and Gonzalez A. Patent ductus arteriosus and respiratory outcome in premature infants. Biol Neonate 88 (2005) 192-201
99. Gonzalez A., Sosenko I.R., Chandar J., et al. Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less. J Pediatr 128 (1996) 470-478
100. Hammerman C., Strates E., and Valaitis S. The silent ductus. its precursors and its aftermath. Pediatr Cardiol 7 (1986) 121-127
101. Varsila E., Hallman M., Venge P., et al. Closure of patent ductus arteriosus decreases pulmonary myeloperoxidase in premature infants with respiratory distress syndrome. Biol Neonate 67 (1995) 167-171
102. Cotton R.B., Stahlman M.T., Bender H.W., et al. Randomized trial of early closure of symptomatic patent ductus arteriosus in small preterm infants. J Pediatr 93 (1978) 647-651
103. Gerhardt T., and Bancalari E. Lung compliance in newborns with patent ductus arteriosus before and after surgical ligation. Biol Neonate 38 (1980) 96-105
104. Harris J.P., Merritt T.A., Alexson C.G., et al. Parenteral indomethacin for closure of the patent ductus arteriosus. Clinical experience with 67 preterm infants. Am J Dis Child 136 (1982) 1005-1008
105. Clyman R.I. Recommendations for the postnatal use of indomethacin. an analysis of four separate treatment strategies. J Pediatr 128 (1996) 601-607
106. Schmidt B., Davis P., Moddemann D., et al. Trial of indomethacin prophylaxis in preterms. I. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med 344 (2001) 1966-1972
107. Maritz G.S., Cock M.L., Louey S., et al. Effects of fetal growth restriction on lung development before and after birth. a morphometric analysis. Pediatr Pulmonol 32 (2001) 201-210
108. Massaro D., Massaro G.D., Baras A., et al. Calorie-related rapid onset of alveolar loss, regeneration, and changes in mouse lung gene expression. Am J Physiol Lung Cell Mol Physiol 286 (2004) L896-L906
109. Parton L.A., Strassberg S.S., Qian D., et al. The genetic basis for bronchopulmonary dysplasia. Front Biosci 11 (2006) 1854-1860